Table of Contents

• Trial overview
• Cancer types studied
• Trial phases and study design
• Who the trials are for
• What the trials measure
• Main Vinorelbine trials in the data
• Patient-focused takeaways

Trial overview

The trial data show that Vinorelbine is being tested in many interventional studies, which means researchers give a planned treatment and then measure the results.^[1] These studies are looking at Vinorelbine in different cancer settings, sometimes alone and often as part of a combination with other anticancer drugs or treatment approaches.^[1]

The studies include both ongoing and completed trials, and they range from small early studies to large international trials.^[1] The data show that Vinorelbine is being explored in Phase 1, Phase 2, and Phase 3 research.^[1]

Cancer types studied

Vinorelbine appears in trials for several cancer types, including non-small cell lung cancer (a common type of lung cancer), breast cancer, colorectal cancer, prostate cancer, lymphoma, Ewing sarcoma, cervical cancer, and some pediatric cancers.^[1]

Some trials focus on advanced disease, such as metastatic colorectal cancer, metastatic breast cancer, or advanced lung cancer.^[1] Other studies focus on earlier stages, such as stage I adenocarcinoma lung cancer after surgery or newly diagnosed Ewing sarcoma.^[1]

Trial phases and study design

In Phase 1 studies, the main goal is usually safety, tolerability, and dose finding.^[1] For example, one prostate cancer study says safety is the primary outcome in Phase I, while another lymphoma study looks for the maximum tolerated dose and the recommended Phase II dose.^[1][2]

In Phase 2 studies, the focus is more on whether the treatment works, while still checking safety.^[1] Examples include trials measuring objective response rate in metastatic colorectal cancer, disease control rate in advanced non-small cell lung cancer, and safety plus efficacy in metastatic medulloblastoma and other embryonal tumours.^[1]

In Phase 3 studies, Vinorelbine is part of larger comparison trials that look at outcomes such as survival or disease control against another treatment plan.^[1] These studies include lung cancer, breast cancer, lymphoma, cervical cancer, and Ewing sarcoma trials.^[1]

Who the trials are for

The target groups vary a lot across the studies.^[1] Some trials are for adults with advanced cancer, such as adults with metastatic colorectal cancer, advanced prostate cancer, or advanced non-small cell lung cancer.^[1]

Other trials include children and adolescents, such as the study in acute lymphoblastic leukemia and the study in pediatric and young adult patients with metastatic medulloblastoma and other embryonal tumours.^[1] Some Ewing sarcoma studies also include young people and use Vinorelbine as part of maintenance treatment or treatment optimization.^[1]

What the trials measure

The most common trial outcomes are measures of how well the cancer responds to treatment and how long the disease stays controlled.^[1] These include overall response rate, disease control rate, progression-free survival, disease-free survival, and event-free survival.^[1]

Several studies also measure safety outcomes, such as adverse events, serious adverse events, dose-limiting toxicities, and treatment stopping because of side effects.^{[1][2] Some trials use scan-based rules like RECIST 1.1, which is a standard way to measure tumor change on imaging scans.[1]}

Main Vinorelbine trials in the data

• Metastatic colorectal cancer: A Phase 2 study of oral and buccal Vinorelbine in 25 patients is looking at objective response rate, with CT scans every 8 weeks to check for complete or partial response.^[1]

• Prostate cancer: A Phase 1 study of Vinorelbine with cisplatin and PET-guided stereotactic ablative radiotherapy is testing safety first, then progression-free survival in later evaluation.^[1]

• Ewing sarcoma: Two large Phase 3 studies use Vinorelbine as maintenance treatment or part of treatment optimization, with event-free survival as the main outcome.^[1]

• Non-small cell lung cancer: Several trials include Vinorelbine in treatment choices for advanced, resectable, or early-stage disease, with outcomes such as disease-free survival, event-free survival, progression-free survival, and resection rate.^[1]

• Breast cancer: Vinorelbine appears in metastatic HER2-positive breast cancer and hormone receptor-positive, HER2-negative breast cancer studies, where researchers compare response and survival outcomes against other chemotherapy choices.^[1]

• Lymphoma: Vinorelbine is part of a Phase 1 study in relapsed or refractory Hodgkin’s lymphoma, where the focus is on dose finding and complete response rate before stem-cell transplantation.^[1]

Patient-focused takeaways

From the trial data, Vinorelbine is not being studied for one single cancer type or one single goal.^[1] It is being tested in many different settings, from early safety studies to large trials that compare treatment plans and survival outcomes.^[1]

For patients, the key point is that each study has its own rules for who can join, what combination is being tested, and which outcome matters most.^[1] That means a trial in lung cancer may look very different from a trial in Ewing sarcoma or lymphoma, even when Vinorelbine is part of the treatment plan.^[1]